Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases by Burren, Oliver S. et al.
RESEARCH Open Access
Genetic feature engineering enables
characterisation of shared risk factors in
immune-mediated diseases
Oliver S. Burren1,2, Guillermo Reales1,2, Limy Wong1,2, John Bowes3,4, James C. Lee1,2, Anne Barton3,4,
Paul A. Lyons1,2, Kenneth G. C. Smith1,2, Wendy Thomson3,4, Paul D. W. Kirk1,5,6 and Chris Wallace1,2,5*
Abstract
Background: Genome-wide association studies (GWAS) have identified pervasive sharing of genetic architectures
across multiple immune-mediated diseases (IMD). By learning the genetic basis of IMD risk from common diseases,
this sharing can be exploited to enable analysis of less frequent IMD where, due to limited sample size, traditional
GWAS techniques are challenging.
Methods: Exploiting ideas from Bayesian genetic fine-mapping, we developed a disease-focused shrinkage
approach to allow us to distill genetic risk components from GWAS summary statistics for a set of related diseases.
We applied this technique to 13 larger GWAS of common IMD, deriving a reduced dimension “basis” that
summarised the multidimensional components of genetic risk. We used independent datasets including the UK
Biobank to assess the performance of the basis and characterise individual axes. Finally, we projected summary
GWAS data for smaller IMD studies, with less than 1000 cases, to assess whether the approach was able to provide
additional insights into genetic architecture of less common IMD or IMD subtypes, where cohort collection is
challenging.
Results: We identified 13 IMD genetic risk components. The projection of independent UK Biobank data demonstrated
the IMD specificity and accuracy of the basis even for traits with very limited case-size (e.g. vitiligo, 150 cases).
Projection of additional IMD-relevant studies allowed us to add biological interpretation to specific components, e.g.
related to raised eosinophil counts in blood and serum concentration of the chemokine CXCL10 (IP-10). On application
to 22 rare IMD and IMD subtypes, we were able to not only highlight subtype-discriminating axes (e.g. for juvenile
idiopathic arthritis) but also suggest eight novel genetic associations.
Conclusions: Requiring only summary-level data, our unsupervised approach allows the genetic architectures across
any range of clinically related traits to be characterised in fewer dimensions. This facilitates the analysis of studies with
modest sample size by matching shared axes of both genetic and biological risk across a wider disease domain, and
provides an evidence base for possible therapeutic repurposing opportunities.
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Background
The collected summary data of genome-wide association
studies (GWAS) represent, in a compressed form, assays
of thousands of phenotypes across millions of common
genetic variants. Analysed individually, GWAS have elu-
cidated the polygenic component of common human
diseases [1], and comparative studies of summary
GWAS results have highlighted a shared genetic aeti-
ology across different diseases [2]. Evidence for such
sharing can highlight opportunities for therapeutic re-
purposing [3]. However, comprehensive overviews of
sharing between multiple diseases are made difficult by
the dimension of these statistics (100,000s of SNPs), the
complex patterns that exist, and the limitation that while
all dimensions carry information about technical differ-
ences between studies (DNA storage, processing, and
population sampling), only a minority carry information
about disease risk. Therefore, integrative analyses have
typically been approached from one of two angles: a
variant-by-variant analysis across multiple diseases fo-
cusing on individual variants in turn [4, 5], or pairwise
analysis of diseases across multiple variants at a regional
or genome-wide level [6, 7]. Both approaches have limi-
tations. Different variants reflect different patterns of
sharing across diseases, making generalisations about
inter-disease relationships difficult, while disease-
pairwise approaches make comparison of more than two
diseases challenging. Thus, a need exists for a framework
to study shared genetic architectures across multiple var-
iants and between multiple diseases simultaneously.
The GWAS approach explicitly accounts for the num-
ber of tests (SNPs) by requiring successively larger sam-
ples (tens of thousands). Large samples present an
insurmountable barrier for rare diseases, where efforts
have instead focused on searching for rare variants of
high penetrance through whole exome [8] or whole gen-
ome [9, 10] sequencing. Despite this, moderate-sized
GWAS-style studies of rare diseases have found both
polygenic association with common variants [10, 11] and
evidence for differential genetic associations between
clinical subtypes of these rare diseases [12]. Thus, a need
exists to democratise GWAS to less common diseases,
which may be possible by considering them in the con-
text of more common, clinically related diseases.
We propose summarising the multifactorial genetic
risks of related diseases in an informed dimension-
reduction approach. Matrix decomposition, for example
via principal component analysis (PCA), expresses a
matrix as the product of two smaller matrices and has
been used extensively as a dimension-reduction tool in
genetics to summarise population structure and address
its confounding effects in association studies [13]. It has
also been used to explore structure in genetic association
with multiple traits, either from different studies
aggregating signals across nearby SNPs [14], or using a
linkage disequilibrium (LD) independent subset of SNPs
from a single cohort [15]. In either case, the reduced di-
mensional space was used to explore the same datasets
as used to define it, with two implications. First, GWAS
summary statistics are a composite of biological signal,
technical noise, and sampling variation. Decomposition
aims to find axes that maximise variance explained in
the input datasets, and cannot distinguish between these
three sources of variability. We therefore expect it to
magnify technical and random differences as well as bio-
logical, a problem related to overfitting in high-
dimensional datasets. Second, in this reduced dimension
space, there is no treatment of uncertainty, so while we
can measure the distance between diseases, we are un-
able to formally assess whether that distance significantly
differs from 0.
Here, we propose augmenting PCA of GWAS summary
statistics by a Bayesian shrinkage approach that mitigates
overfitting. Our central aim is to define a reduced dimen-
sion space, with components that describe different pat-
terns of genetic susceptibility corresponding to underlying
biological risk factors. In a transfer learning paradigm, we
can project independent datasets into this space, allowing
us to study the distinct and shared genetic contributions
to related diseases, and use standard statistical techniques
to test for genetic association of rare diseases or genetic
differences between disease subtypes. We use immune-
mediated diseases (IMD) as an example of a set of traits
with established aetiological overlap [2] to highlight the
potential uses of this method.
Methods
Method for constructing a common genetic basis for
related diseases
We aimed to decompose common components under-
lying susceptibility to a set of related diseases using
PCA. There are three particular challenges with per-
forming PCA on GWAS summary statistics. First, the
SNP effect estimates (e.g. log odds ratios, denoted β̂ )
must be on the same scale; second, we must deal with
variable correlation between input dimensions (SNPs)
due to LD; and third, while all SNPs are expected to
show small deviations between studies due to random
noise, different genotyping platforms, and data process-
ing decisions, only a minority of SNPs will be truly re-
lated to the diseases of interest.
The uncertainty attached to β̂ depends on both study
sample size and SNP minor allele frequency (MAF). We
adjusted for the variance in β̂ due to MAF, σ2MAF, as this
varies between SNPs, but not variance due to sample
size, as this would overly shrink smaller studies relative
to larger. To ensure the disease relevance of the basis,
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we wanted to preferentially use information from truly
associated SNPs, while avoiding double counting evi-
dence from SNPs in LD. We therefore dealt with the lat-
ter two challenges simultaneously, using a Bayesian fine-
mapping technique which calculates the “posterior prob-
ability” that each SNP is causal for each trait, under the
assumption that at most one causal variant exists in each
recombination hotspot-defined block of SNPs [16, 17].
Note that the method also assumes the causal variant is
in the dataset, an assumption likely to be violated with-
out dense GWAS data. We thus use the method not to
interpret the output as genuine probabilities, but for its
side effect of generating a shrinkage weight that natur-
ally adjusts for LD. At each SNP, we computed a
weighted average of the posterior probabilities across in-
put studies to create an overall weight for that SNP, w.
w will be close to zero when there is no association in a
region, limiting the influence of technical noise between
studies, and will otherwise act to weight associated SNPs
according to the extent of LD in a region. The final in-
put for basis creation is a matrix of γ̂ ¼ wβ̂=σMAF .
A mathematically detailed summary is given in Add-
itional File 1, and a summary of the method is shown in
Fig. 1.
Construction of IMD basis
We identified 13 IMD GWAS with > 6000 samples of
European ancestry for which full summary statistics
were publicly available (Additional File 2: Table S1).
Studies were chosen to balance the competing aims of
maximising the number of studies, the number of SNPs
common to all studies, and the number of samples in
each study (to minimise noise in β̂). We selected SNPs
present in all 13 studies, with MAF > 1% in the 1000 Ge-
nomes Phase 3 EUR data. We excluded all variants
Fig. 1 Schematic of basis creation and projection. Basis creation: GWAS summary statistics for related traits are combined to create a matrix, M
(n ×m), of harmonised effect sizes (β̂) and a learnt vector of shrinkage values for each SNP. After multiplying each row of M by the shrinkage
vector, PCA is used to decompose M into component and loading matrices. Basis projection: for an independent set of studies, trait effects are
harmonised with respect to the basis, shrinkage applied, and the resultant vector is multiplied by the basis loading matrix to obtain component
scores. These component scores can be used for testing hypotheses of the form that a weighted average of effect sizes in the test GWAS is non-
zero, because the weights (basis loading matrix) are learnt from an independent set of large GWAS
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within the major histocompatibility complex (MHC,
GRCh37 Chr6:20-40Mb) due to its long and complex
LD structure, and because SNPs in the MHC have a pro-
found involvement in IMD susceptibility, and thus the
potential to dominate the basis. We also excluded SNPs
for which the unambiguous assignment of the effect al-
lele was impossible (e.g. palindromic SNPs). We harmo-
nised all effect estimates to be with respect to the
alternative allele relative to the reference allele as defined
by the 1000 Genomes reference genotype panel. After
filtering, harmonised effect estimates were available for
265,887 SNPs across all 13 selected “basis” traits (Add-
itional File 3: Fig. S1), and additional analyses of a subset
of six datasets with dense genotyping showed that these
265,887 SNPs adequately tagged the information avail-
able in the full SNP data (Additional File 1). In order to
provide a baseline for subsequent analyses, we created
an additional synthetic control trait, for which effect sizes
across all traits were set to zero. This can be thought of as
the limit of a simulated null GWAS as the number of
cases and controls tends to infinity (Additional File 1). We
used these to construct two matricesM and M′ where ele-
ments reflect raw ( β̂ ) and shrunk effect sizes ( γ̂ ¼ wβ̂=
σMAF ), respectively, such that rows and columns reflect
traits (n = 14) and SNPs (p = 265,887). After mean cen-
tring columns, we used the R command prcomp to carry
out PCA of both M and M′ to generate naive and
“shrunk” IMD bases. It is likely that the trailing compo-
nents of any PCA represent noise, so to assess the max-
imal subset of informative components, we examined the
mean squared reconstruction error and found that the
fewest components needed to minimise this error were
m= n − 1 = 13 (Additional File 3: Fig. S2). We therefore
discarded the final 14th component. As in conventional
PCA, this basis consists of orthogonal principal compo-
nents (PCs), constructed as linear functions of input β̂ ,
which together provide a lower dimensional representa-
tion of genetic associations with IMD.
Driver SNPs
We noted that the majority of entries in the p ×m PCA
rotation matrix, Q, were close to 0, and chose to hard
threshold these to 0 for computational efficiency and to
identify which driver SNPs were relevant to each compo-
nent. To do this, using Qk to represent the kth column
of Q, we define Qk (α) =Qk x I (|Qk|>α) where I () is an
indicator function and “x” represents element-wise
multiplication. We quantify the distance between projec-
tion with Qk and Qk(α) by:
Dk αð Þ ¼ 1 − cor Mc Qk ;Mc Qk αð Þð Þ:
where MC is the centred matrix of shrunk effect sizes
M′, defined above. We chose the threshold for each
component, αk, as the largest value α such that Dk (α) <
0.001. Finally, we defined the sparse basis rotation
matrix as the matrix constructed from the column vec-
tors Qk, k = 1,...,m. This identified both driver SNPs
which define the support for each component, and en-
abled computationally efficient examination of many
traits in the reduced dimension space defined.
Projection of independent datasets
We constructed a compendium of publicly available
GWAS summary statistics across a wide range of traits
including UK Biobank (UKBB) self-reported traits
(http://www.nealelab.is/uk-biobank, http://geneatlas.
roslin.ed.ac.uk/—Additional File 2: Tables S2-S3), IMD-
relevant GWAS (Additional File 2: Table S4), and
GWAS of quantitative measures from blood count data
[18], immune cell counts [19], and cytokine levels [20]
(Additional File 2: Tables S5-S7). Disease GWAS data
were obtained from the URL given or via request to
study authors, with the exception of anti-neutrophil
cytoplasmic antibody (ANCA)-associated vasculitis
(AAV), juvenile idiopathic arthritis (JIA), and psoriatic
arthritis (PsA) which are described in Additional File 4
and data given in Additional File 5, Table S9.
Prior to projection, effect alleles were aligned to the
1000 Genomes reference genotype panel. For traits sen-
sitive to missing data (studies of neuromyelitis optica
(NMO) [10], and 8 by Aterido [21] see Additional File
1), we imputed missing variants using ssimp [22] (v 0.5.6
--ref 1KG/EUR --impute.maf 0.01); otherwise, we set ef-
fect estimates to zero. Data were then shrunk as for the
basis traits (multiplying by w/σMAF), and projected into
basis space by multiplying by the sparse basis rotation
matrix Q. We report projected results as δ̂ , the differ-
ence between the projected β̂ and a projected synthetic
control with all entries 0, which allows us to make statis-
tical inference about whether its estimand, δ, differs
from control. We calculated variance of δ̂ as described
in Additional File 1.
GWAS test multiple null hypotheses of the form β = 0
to identify disease-associated SNPs. This approach has
been extended to test genetic correlation through cross-
trait polygenic score tests. A SNP set and weights are
learnt to optimise genetic prediction of a trait of interest,
and the weighted sums of β are constructed in a second
dataset, and tested for association with a second trait of
interest [23]. We consider each component in the basis
to be a polygenic score for an uncharacterised factor
contributing to one or more basis input traits. We
looked for an association of the projected traits to any
component by testing the null hypothesis that the vector
δ = 0 across all 13 components using a chi-square test
(Additional File 1: eq. 2). This null hypothesis is related
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to the global GWAS null hypothesis of no association,
but is restricted to the small number of components
identified in the basis, which are formed as a weighted
linear function of a subset of variants. Failure to reject
this null could reflect either a lack of power (as with all
GWAS) or a lack of genetic association with the com-
mon components shared by the basis diseases. We called
significant associations according to FDR < 0.01, calcu-
lated using the Benjamini-Hochberg approach, run inde-
pendently within the broad categories: primary analysis
(UKBB self-reported disease and cancer, plus IMD-
relevant GWAS), blood cell counts, cytokines, and im-
mune cell counts. This was our primary measure of sig-
nificance. We took the same strategy to independently
calculate FDR for each component individually for add-
itional annotation, and traits were considered “compo-
nent-significant” if they were significant (component
FDR < 0.01) on that component and overall.
Classification of diseases according to autoantibody
status was performed by a specialist clinician using avail-
able medical literature. This assignment was blinded to
the PC1 results.
Clustering
We used the hclust () function in R to cluster diseases in
the basis using agglomerative hierarchical clustering ac-
cording to Ward’s criterion (method = “Ward.D2”) on
the Euclidean distance between projected locations of
each disease in the basis.
Consistency
We would like to interpret significant results as repre-
senting a composite of many small effects working in
consistent directions. However, false positives could also
occur if a single SNP with a large weight in the basis is
in LD with a SNP with a large effect on the projected
trait due to chance. To guard against this, we used
weighted Spearman rank correlation which is robust to
such outlier observations to test the “consistency” of
each projection on a subset of driver SNPs in low LD
(r2 < 0.01), with weights w/σMAF and significance deter-
mined by permuting the projected values. All projected
values are given in Additional File 6: Table S10.
Candidate significant driver SNPs
For each of 10 diseases or subtypes with < 2000 cases
and significant on at least one component (myasthenia
gravis, late onset; eosinophilic granulomatosis with poly-
angiitis [EGPA], myeloperoxidase positive [MPO+],
ANCA negative [ANCA−], and combined; JIA, extended
oligoarticular [EO], persistent oligoarticular [PO], and
polyarticular rheumatoid factor positive/negative [RF+
and RF−, respectively]), we selected all driver SNPs on
any significant component and calculated the FDR
within this set of SNPs as a subset-selected FDR [24].We
ordered SNPs by increasing values of ssFDR and deleted
any SNPs in the list that were in LD (r2 > 0.1) with a
higher placed SNP, leaving a set of unlinked SNPs asso-
ciated with each trait shown in Table 1. These were an-
notated through literature searches.
Results
A genetic basis for immune-mediated diseases
To illustrate the importance of our informed shrinkage
procedure, we built four bases, with GWAS summary
statistics for the 13 IMD shrunk differently in each case.
We assessed their relative performance by projection of
matching self-reported diseases (SRD) from UK BioBank
(UKBB) [26] using summary statistics from a compen-
dium provided by the Neale lab [http://www.nealelab.is/
uk-biobank/], and used hierarchical clustering to exam-
ine whether expected patterns of similarities between
diseases are captured in each reduced dimension space.
The first was a naive approach without any shrinkage.
Here, the UKBB SRD clustered with each other rather
than their GWAS comparator, suggesting that the struc-
ture identified related to between-study differences other
than disease (Fig. 2). In contrast, in the basis created
with continuous shrinkage, all selected UKBB SRD
clearly clustered with their GWAS comparators (Fig. 2),
suggesting that the structure captured is disease-
relevant, such that UKBB data from relatively infrequent
diseases such as type 1 diabetes (T1D) (318 cases) and
vitiligo (105 cases) are projected onto the same vectors
as their larger comparator GWAS.
To illustrate the importance of using continuous
shrinkage, we compared it to hard-thresholding, as used
in the single-dataset decomposition approach, DeGAs
[15], which replaced β̂ by Z scores, and set Z = 0 when
the associated p > 0.001. As Z scores are standardised β̂,
this has the effect of shrinking β̂ towards 0 when uncer-
tainty is high, such as when allele or disease frequencies
are low, which means information from more common
diseases will dominate. We generated hard-thresholded,
LD-thinned bases using either Z scores or β̂ . For these,
some of the structure identified was disease-related for
the larger GWAS of more common traits (asthma, mul-
tiple sclerosis [MS], Crohn’s disease [CD], ulcerative col-
itis [UC]), but the smaller diseases were dominated by
dataset-specific structure (Additional File 3: Fig. S3).
We projected data from three classes of study onto the
basis with shrinkage. First, we used all self-reported dis-
ease and cancer traits from UKBB to characterise the
basis components, to examine specificity to IMD, and to
assess power as a function of sample size: case numbers
for UKBB self-reported IMD range from 41,000 (asthma)
to 105 (vitiligo). Second, we used IMD GWAS with
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Table 1 Disease-associated SNPs identified through subset-selected FDR (ssFDR) < 0.01 amongst driver SNPs belonging to disease-
significant components. Genes listed are nearby genes previously mentioned in the literature for the listed disease or basis diseases
associated to this SNP, and are intended to indicate location; no evidence for gene causality has been assessed here. Where no
basis diseases are associated with the SNP at genome-wide significant threshold (GWsig, p < 5 × 10−8), the strongest association and
its p value are shown




JIA RF− rs2476601 1 114,377,
568
2.36E−13 7.68E−11 PTPN22 CD, RA, SLE,
T1D, VIT
EGPA combined rs13405741 2 111,913,
056
2.89E−09 1.07E−06 BCL2L11 PSC
EGPA ANCA− rs11745587 5 131,796,
922
3.59E−08 1.33E−05 IRF1/IL5 Asthma, CD
JIA RF− rs11065987 12 112,072,
424
1.87E−08 2.81E−06 SH2B3 PBC, T1D,
VIT
Genome-wide significant in another subtype or study (7)
JIA PO rs2476601 1 114,377,
568
7.59E−06 3.65E−03 PTPN22 CD, RA, SLE,
T1D, VIT






6.62E−05 2.61E−03 PTPN22 CD, RA, SLE,
T1D, VIT
GWsig in myasthenia gravis
EGPA ANCA− rs13405741 2 111,913,
056
1.33E−06 2.46E−04 BCL2L11 PSC GWsig in EGPA combined
JIA EO rs7574865 2 191,964,
633






8.57E−07 1.69E−04 CTLA4 RA, T1D r2 > 0.5 with non-driver SNP





1.18E−05 2.33E−03 CTLA4 RA, T1D r2 > 0.5 with non-driver SNP
rs231770, p = 3.98E−08
JIA RF− rs1893217 18 12,809,
340
1.69E−06 1.10E−04 PTPN2 CD, RA, T1D GWsig in JIA combined
Supported by other evidence in another study (5)
EGPA combined rs11745587 5 131,796,
922
3.44E−07 6.38E−05 IRF1, IL5 Asthma, CD GWsig conditional on asthma GWAS
EGPA combined rs6454802 6 90,814,
199
8.73E−06 6.48E−04 BACH2 Asthma,
T1D, VIT
GWsig conditional on eosinophil count GWAS
EGPA ANCA− rs6454802 6 90,814,
199
1.23E−05 1.52E−03 BACH2 Asthma,
T1D, VIT
GWsig conditional on eosinophil count GWAS
EGPA combined rs8179 7 92,236,
164
6.05E−06 5.61E−04 CDK6 RA 4.3e−07 GWsig conditional on eosinophil count GWAS
EGPA ANCA− rs8179 7 92,236,
164
5.51E−05 3.34E−03 CDK6 RA 4.3e−07 GWsig conditional on eosinophil count GWAS
Not previously reported (8)
JIA RF− rs9594746 13 42,989,
660
1.06E−05 4.91E−04 TNFSF11 PBC 4.7e−07 r2 = 0.9 with rs34132030 (p = 2 × 10−7 in larger
dataset [25])
EGPA combined rs12405671 1 117,263,
868
2.99E−06 3.70E−04 CD2, CD28 RA 1e−07
EGPA ANCA− rs12405671 1 117,263,
868
4.06E−05 3.04E−03 CD2, CD28 RA 1e−07





Asthma NB unlinked to nearby and previously reported
EGPA-associated rs1837253 (r2 = 0.01)




Asthma NB unlinked to nearby and previously reported
EGPA-associated rs1837253 (r2 = 0.01)
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smaller sample sizes than used in basis construction, in-
cluding diseases studied in multiple ancestral back-
grounds to explore robustness to ancestry differences.
Third, we used the basis to analyse studies of IMD that
are too rare or clinically heterogeneous to build large
GWAS cohorts.
Genetic analysis of multiple IMD in reduced dimensions
Across all 312 projected UKBB traits (Additional File
2: Table S2), 27 had significantly non-zero δ̂ (FDR <
1%). These were overwhelmingly immune-related
traits (Fig. 3): no significance was observed for traits
such as coronary artery disease, stroke, or obstructive
sleep apnoea, confirming the immune-mediated speci-
ficity of our basis. Significant results were detected
with as few as 105 cases for vitiligo, emphasising the
potential of this approach to unlock the genetics of
rare IMD GWAS.
Of 28 traits from target (non-UKBB) IMD GWAS, in-
cluding JIA, NMO, vasculitis, and their clinical subtypes,
16 were significant (FDR < 1%, Additional File 2: Table
S3, Additional File 3: Fig. S4-S16). We found, reassur-
ingly, that increasing evidence for non-zero δ on any
component correlated with increasing consistency on
that component (see the “Methods” section) amongst
disease traits (Additional File 3: Fig. S17), suggesting that
significant results were produced by an average effect
over many driver SNPs rather than random overlap of a
small number of driver SNPs with trait-associated SNPs.
We clustered all 28 target traits and all 27 significant
UKBB self-reported traits to generate a visual overview
of IMD and associated traits (Fig. 4). Hierarchical clus-
tering solutions are generally unstable and dependent on
Table 1 Disease-associated SNPs identified through subset-selected FDR (ssFDR) < 0.01 amongst driver SNPs belonging to disease-
significant components. Genes listed are nearby genes previously mentioned in the literature for the listed disease or basis diseases
associated to this SNP, and are intended to indicate location; no evidence for gene causality has been assessed here. Where no
basis diseases are associated with the SNP at genome-wide significant threshold (GWsig, p < 5 × 10−8), the strongest association and
its p value are shown (Continued)














6.01E−05 5.95E−03 IRF1, IL5 Asthma, CD
EGPA combined rs10876864 12 56,401,
085
1.19E−04 4.42E−03 SUOX, IKZF4 T1D, VIT
Fig. 2 Hierarchical clustering of basis diseases and their UKBB counterparts in basis space. a Unweighted basis constructed using β̂. b Basis
constructed using continuous shrinkage applied to β̂. Heatmaps indicate projected δ̂ for each disease on each component PC1–PC13, with grey
indicating 0 (no difference from control), and darker shades of green or magenta showing departure from controls in one direction or the other.
GWAS datasets: T1D, type 1 diabetes; CEL, celiac disease; asthma; MS, multiple sclerosis; UC, ulcerative colitis; CD, Crohn’s disease; RA, rheumatoid
arthritis; VIT, vitiligo; SLE, systemic lupus erythematosus; PSC, primary sclerosing cholangitis; PBC, primary biliary cholangitis; LADA, latent
autoimmune diabetes in adults; IgA_NEPH, IgA nephropathy. UKBB_ prefixed diseases correspond to self-reported disease status in UK Biobank
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the composition of the items to be clustered, as well as
the method used for clustering [27]. While clustering
provides only a visual overview rather than a formal stat-
istical analysis of trait similarity, it highlighted two small
disease groups, inflammatory bowel disease (IBD) and
EGPA, and two larger groups, one comprising auto-
immune diseases and the other a heterogeneous cluster
containing subgroups centred on MS, ankylosing spon-
dylitis (AS), atopy, and traits with only weak or non-
significant signals. Notably, three studies of AS all clus-
tered together, despite only one having sufficient sample
size for significant results and the three studies repre-
senting different ancestries (UK-European, International,
and Turkish/Iranian).
While our basis was created from predominantly Euro-
pean GWAS, there is an imperative to increase ancestry
diversity in GWAS [28]. We undertook a search for avail-
able IMD GWAS data with coverage of non-European an-
cestry and identified 6 studies of asthma, RA, UC, and CD
in African and/or East Asian ancestry populations (Add-
itional File 2: Table S8). Projecting these onto the basis,
we find that all significant points have the same sign of
delta for any given ancestry and PC combination (Add-
itional File 3: Fig. S18). Thus, results are consistent across
GWAS of the same traits in populations with different an-
cestry backgrounds. A broader examination comparing
projections of all ~ 452,000 UKBB subjects to the Euro-
pean subset of 360,000 subjects found that while the
mixed ancestry GWAS tended to result in slightly attenu-
ated estimates of δ̂ , the increased sample size also led to
increased power compared to smaller European GWAS
(Additional File 3: Fig. S19).
Most disease subtypes clustered together (Fig. 4). For
example, myasthenia gravis, a chronic, autoimmune,
neuromuscular disease characterised by muscle weakness,
has been shown to have a bimodal incidence pattern by
age, and some genetic associations have been identified
only for the late-onset subtype [29]. However, both
Fig. 3 Of 312 UKBB self-reported traits projected onto the basis, 27 were significant at FDR < 1%, and IMD were enriched amongst this set, with
63% of IMD showing significance compared to < 3% of non-IMD traits. Each trait projected is shown according to FDR (−log10 scale, axis
truncated at FDR = 10−6 for display) and number of cases. All IMD (yellow) and all significant non-IMD traits (grey) are labelled
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Fig. 4 (See legend on next page.)
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subtypes fell in very similar locations across all compo-
nents and cluster together with several subtypes of JIA.
For two other diseases, however, subtypes clustered
apart. NMO is a rare (prevalence 0.03–0.4:10,000) dis-
ease affecting the optic nerve and spinal cord for which
HLA association is established [10] and which can be di-
vided according to aquaporin 4 autoantibody seroposi-
tivity status (IgG+ or IgG−). The projections of
seropositive and seronegative NMO showed non-
significant differences on several components, leading to
differential clustering. While seropositive NMO clus-
tered with the classical autoimmune diseases, most
closely with systemic lupus erythematosus [SLE] and
Sjögren’s disease, IgG− NMO clustered away from the
classic seropositive diseases, most closely with MS. This
finding mirrors analysis which directly compared NMO
subtypes to each of SLE and MS via polygenic scores
[10], and strengthens the findings by specifically suggest-
ing SLE and MS as the nearest neighbours of IgG+ and
IgG− NMO, respectively, out of all IMD considered for
clustering.
JIA is a heterogeneous paediatric disease, with an over-
all childhood prevalence in Europe of 20/10,000 [30],
and with seven recognised subtypes [31]. While studies
have begun to identify distinct genetics of the systemic
subtype [32] and have shown subtype-specific differences
in the MHC [33], systematic comparison between sub-
types has been underpowered. Although, the systemic
and enthesitis-related arthritis (ERA) subtypes did not
significantly differ from controls (despite relatively mod-
erate sample sizes of 219 and 267 cases, respectively),
they clustered with MS and AS, respectively, and away
from the other JIA subtypes, which clustered with the
other autoimmune diseases.
Association of driver SNPs to rare IMD or subtypes
Given that most of the IMD and subtypes with small
GWAS have few established genetic associations, we
sought to exploit the component-level associations above
to detect new disease associations. Our basis has only 13
dimensions. If genetic susceptibility to rare IMD and
IMD subtypes overlaps that of common IMD, we can in-
crease power by focusing on these dimensions. Of 22
diseases or disease subtypes with < 1000 cases, 12 were
significant (FDR < 1%), even with as few as 132 cases
(NMO IgG+).
Although not a specific goal, the basis generated is
naturally sparse (Additional File 3: Fig. S20), enabling us
to identify 107–373 “driver SNPs” that are required to
capture genetic associations on any individual compo-
nent. We found a strong enrichment for small GWAS p
values at driver SNPs on trait-significant components
(Additional File 3: Fig. S21). Using a “subset-selected”
FDR approach [24], we analysed driver SNPs for 22 sig-
nificant trait-component pairs (12 unique traits) and
identified 25 trait-SNP associations (subset-selected
FDR < 1%, Table 1) after pruning SNPs in LD. Twelve of
these were genome-wide significant (p < 5 × 10−8) either
in this study (4 associations) or in other published data
(8 associations), and a further five were significant in
other published analysis that levered external data.
These included, for example, the non-synonymous
PTPN22 SNP rs2476601 which was associated with my-
asthenia gravis (overall and the late-onset subset) by
subset-selected FDR < 0.01. This SNP was previously as-
sociated with myasthenia gravis in a different study [34],
and lack of clear replication in the data analysed here
(p = 6 × 10−5) was attributed to differences in population
structure. Eight associations (five variants) were not pre-
viously reported to our knowledge, including associa-
tions near IRF1/IL5 for myasthenia gravis, near TNFS
F11 for RF− JIA, and near CD2/CD28 for EGPA.
Component interpretation
PC1, which explained the greatest variation in the train-
ing datasets, appears to represent an autoimmune/
(auto)inflammatory axis [35], also characterised by
whether diseases are considered antibody “seropositive”
or “seronegative” (Fig. 5). The exception is vitiligo, in
which, despite strong evidence of T cell autoimmunity,
autoantibodies are reported but are not consistent fea-
tures of disease [36]. Weaker but significant association
of psoriatic arthritis (PsA) amongst the other seroposi-
tive IMD is also consistent with a recent report of novel
pathogenic antibodies in PsA [37]. On the inflamma-
tory/seronegative side, we also saw weaker but still sig-
nificant signals for atopy, basal cell carcinoma, and
malignant melanoma. Both malignant melanoma and
(See figure on previous page.)
Fig. 4 Hierarchical clustering of projected diseases significantly different from control (FDR < 1%) or of small sample size. Coloured labels are used to
distinguish UKBB (grey) and other GWAS (green) datasets. Heatmaps indicate delta values for each disease on each component PC1–PC13, with grey
indicating 0 (no difference from control), and darker shades of blue or magenta showing departure from controls in one direction or the other. An
overlaid “*” indicates delta was significantly non-zero (FDR < 1%). Roman numerals indicate clusters described in the text. ANCA−, anti-neutrophil
cytoplasmic antibody negative; Ank. Spond, ankylosing spondylitis; EGPA, eosinophilic granulomatosis with polyangiitis; EO, extended oligo; ERA,
juvenile enthesitis-related arthritis; IgGPos, IgG positive; JIA, juvenile idiopathic arthritis; MPO+, myeloperoxidase positive; NMO, neuromyelitis optica;
PO, persistent oligo; PR3+, proteinase 3 positive; PsA, psoriatic arthritis; RF+/−, polyarticular rheumatoid factor positive/negative; SLE, systemic lupus
erythematosus; UC, ulcerative colitis
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non-melanoma skin cancer incidence is increased in
IBD, but the relative role of treatment or IBD itself in
driving this is hard to determine [38, 39]. On the sero-
positive side, we saw significant results for pernicious
anaemia, a disease strongly associated with anti-gastric
parietal cell and anti-intrinsic factor antibodies, as well
as with autoimmune thyroiditis, T1D, and vitiligo [40].
To help characterise the biology captured by indi-
vidual components, we projected additional datasets:
blood counts [18], immune cell counts [19], and
serum cytokine concentrations [20] (Additional File 2:
Tables S5, S6, and S7). Testing for consistency identi-
fied outliers in the blood count data, which had been
generated from a much larger sample, and so we add-
itionally filtered on consistency in that dataset. These
data aided interpretation of two further components.
PC13 was striking for the general association of many
diseases across all four main clusters in a concordant
direction and was the only component for which any
projected trait was more extreme than any original basis
trait (Fig. 6). The most extreme was EGPA, both
ANCA+ and ANCA− subtypes. EGPA is a rare form of
Fig. 5 Forest plots showing projected values for diseases significant overall and on components 1. Grey square dots indicate projected data and
95% confidence intervals. Red dots indicate the 13 IMD used for basis construction and for which no confidence interval is available. Points to the
right of each line indicate disease classification according to whether they have specific autoantibodies that are either directly implicated in
disease pathogenesis (“pathogenic”) or which are specific to the disease, but not involved in pathogenesis (“non-pathogenic”). Diseases that are
not associated with specific autoantibodies were classified as “none”. ANCA−, anti-neutrophil cytoplasmic antibody negative; Ank. Spond,
ankylosing spondylitis; EGPA, eosinophilic granulomatosis with polyangiitis; EO, extended oligo; ERA, juvenile enthesitis-related arthritis; IgGPos,
IgG positive; JIA, juvenile idiopathic arthritis; LADA, latent autoimmune diabetes in adults; NMO, neuromyelitis optica; PO, persistent oligo; PsA,
psoriatic arthritis; RF+/−, polyarticular rheumatoid factor positive/negative; SLE, systemic lupus erythematosus; UC, ulcerative colitis
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AAV (annual incidence 1–2 cases per million) for which
genetic differences relating to autoantibody status have
been identified [12]. We found PC13 was strongly asso-
ciated with higher eosinophil counts in a population co-
hort [18] (FDR < 10−200), suggesting that this component
describes eosinophilic involvement in IMD. This is con-
sistent with the extreme projection of EGPA which is
classified as an eosinophilic form of AAV with both
asthma and raised eosinophil count included in its diag-
nostic criteria.
Eosinophils are pro-inflammatory leukocytes with an
established role in atopic diseases such as asthma
[41], inflammatory diseases such as IBD [42], and
autoimmune diseases such as RA [43]. Mendelian
randomisation (MR) analysis of blood cell traits had
previously further associated eosinophils with celiac
disease (CEL), asthma, and T1D [18]. Our analysis
thus supports earlier findings and extends the list of
IMD with genetically supported involvement of eosin-
ophils to include EGPA, JIA subtypes, AS, ATD, MS,
hay fever, and eczema, in agreement with other recent
findings [44].
PC3 (Fig. 7) was the only component which showed a
significant relationship with any serum cytokine concen-
tration. Higher concentrations of CXCL9 (MIG) and
CXCL10 (IP-10), Th1 chemoattractants and ligands to
Fig. 6 Forest plot of significant traits on PC13 which also shows association with eosinophil counts in blood. ANCA−, anti-neutrophil cytoplasmic
antibody negative; Ank. Spond, ankylosing spondylitis; EGPA, eosinophilic granulomatosis with polyangiitis; JIA, juvenile idiopathic arthritis; MPO+,
myeloperoxidase positive; PO, persistent oligo; RF−, polyarticular rheumatoid factor negative
Burren et al. Genome Medicine          (2020) 12:106 Page 12 of 17
the regulator of leukocyte trafficking CXCR3, were both
significant in the same direction as several autoimmune
diseases, with strongest signals for myasthenia gravis,
and several JIA subtypes, as well as IBD, CEL, AS, and
sarcoidosis. IP-10 and MIG are chemokines, secreted by
epithelial and dendritic cells (amongst others), which act
as chemoattractants for immune cells which express the
receptor CXCR3, including Th1 cells. Both MIG and IP-
10 expression at the site of autoimmune target have
been implicated in the development of autoimmunity
[45, 46], and IP-10 has been observed to be upregulated
in follicular cells of patients with myasthenia gravis [47].
Serum IP-10 has also been found to be raised in patients
with recent-onset T1D [48, 49] and Graves’ disease
(hyperthyroidism) [46], and to correlate with increased
disease activity in SLE [50] and AS [51].
Discussion
Our motivation in this work was threefold. The first
is to overcome the problems of dimensionality and
allow an overview of genetic association patterns from
multiple related diseases without oversimplification.
While previous efforts to relate different traits
through GWAS statistics have focused on large stud-
ies and shown that they can distinguish broad classes
of immune-mediated, cardiovascular, and metabolic
diseases [6, 14], we have tackled the problem of find-
ing structure within a single class of diseases. Unlike
other applications of PCA to genetics, we split our
datasets into “training” and “test” sets, enabling stand-
ard statistical hypothesis testing and providing robust-
ness against overfitting. Importantly, our method
allows synthesis of knowledge from different studies,
Fig. 7 Forest plot of significant traits on PC3 which also shows association with serum cytokine levels of IP-10 (CXCL10) and MIG (CXCL9). EO,
extended oligo; PO, persistent oligo; RF+/−, polyarticular rheumatoid factor positive/negative; UC, ulcerative colitis
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allowing large numbers of cases from different dis-
eases to contribute to the constructed dimensions.
Our second motivation was to generate new know-
ledge in rare IMD. The number of polymorphic human
genetic variants together with our understanding that
genetic effects on human disease are generally modest
has led to massive GWAS to overcome the penalty that
must be applied for multiple testing. This is simply not
possible for rare diseases. One of the tools which has en-
hanced rare disease GWAS is the borrowing of informa-
tion from larger GWAS of aetiologically related diseases
[12], and our basis serves a similar function here. By le-
veraging information about a SNP’s potential to be
IMD-associated, we can both increase genetic discovery
and place less common diseases in the context of their
more prevalent counterparts. More generally, studies of
SRD are being enabled on a massive scale by UKBB [52]
and 23andMe [53], although studies of such cohorts
tend to focus on the more common diseases such as
type 2 diabetes (T2D) and coronary heart disease. Our
results provide reassurance that SRD associations are
consistent with those from targeted GWAS, and extend
their utility to IMD and other diseases which are gener-
ally found at a lower frequency.
Our final motivation was to extract different axes
underlying IMD genetic risk. Works in metabolic [54]
and psychiatric [55] diseases have attempted to learn
composite factors underlying risk of these related dis-
eases through deeper phenotyping of patients before
testing these factors for genetic association. Alterna-
tively, decomposition of estimated effects at 94 T2D risk
variants, together with their effects on 46 metabolic
traits, was used to cluster variants into 5 groups, three
focused on insulin resistance and two on beta cell func-
tion [56]. Here, we hoped to learn the same sorts of fac-
tors by decomposing only summary GWAS data on
clinical disease endpoints. Our continuous shrinkage
weight learnt across all training datasets enables us to
extract disease-relevant structure, with projected traits
lying close to their training data counterparts, something
achieved with disease-specific hard-thresholded weights
[15] for only the largest datasets.
There are limitations with the method. The assumption of
a single causal variant per disease, and per LD-defined re-
gion, in generating SNP weights is obviously unrealistic.
However, it is this simple assumption that allows us to
process summary GWAS data from multiple studies without
accurate LD estimates from each study. The assumption,
while simplistic, has nonetheless been used in both fine-
mapping and colocalisation analyses, because in most cases it
means only the strongest signal in each region is considered
per disease [57]. More sophisticated fine-mapping methods
which can cope with multiple causal variants in LD will be
required to adapt our method to the MHC which harbours
many of the strongest IMD effects. A more impactful limita-
tion is likely to be that signals in projected datasets can only
be discovered if they are also captured in the diseases used to
build the basis. Thus, the careful selection of plausibly rele-
vant traits is important, and a negative result for a projected
dataset only means no detected association with the identi-
fied components, and not an absence of genetic association.
For example, the relative underrepresentation of atopic dis-
eases in our input datasets may underlie the relative lack of
associations seen for allergy and eczema. The number of
available input datasets also limits the number of compo-
nents that may be distinguished to the rank of the matrix of
shrunk effect sizes, which cannot be greater than the number
of datasets. For both these reasons, future work will seek to
expand the number of datasets included to develop a more
comprehensive IMD basis.
We found components defined using the largest GWAS of
IMD we could access showed different patterns of associ-
ation with different disease subsets, emphasising the utility of
a multidimensional view. The autoimmune/(auto)inflamma-
tory axis in IMD represented by PC1 is well documented,
with the gradient along PC1 corresponding to a shift from
autoantibody seronegative to seropositive diseases. Significant
IMD on the MIG/IP-10-associated PC3 included both “sero-
positive” and “seronegative” diseases, although not atopy,
while all three groups were represented on the eosinophil-
associated PC13. While these observations support a link be-
tween certain IMD and serum cytokine levels or blood cell
counts, our results do not directly implicate these as causal.
Both cytokines and blood count data were measured in unse-
lected population cohorts which will include individuals with
IMD, such that the association with IMD may be causal or
consequential. For example, we can conclude only that PC3
represents an IMD-related process that contributes to serum
cytokine levels. Nonetheless, clinical efficacy of MDX1100, a
monoclonal antibody to IP-10, has been demonstrated in RA
[58] and a dose-response relationship observed in UC [59].
Our results suggest IP-10 blockade might also be considered
in patients with myasthenia gravis, JIA, AS, and sarcoidosis.
Conclusions
Our proposed approach may be considered a form of
feature engineering. We represent genetic associations
for aetiologically related traits using radically fewer fea-
tures, with attached estimates of uncertainty. This en-
abled us to identify clusters of IMD and nominate
involvement of IP-10 and eosinophil counts as involved
in a wider range of IMD than previously suggested. Such
observations provide a rationale for potential therapeutic
repurposing opportunities. Beyond these uses, we expect
that reduced dimensional representation of multiple
genetic association datasets will offer a foundation for
other novel cross-disease analyses within and beyond the
immune-mediated focus here.
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